Like what you see? If you want to learn more about opportunities to join the #ProthenaProud team, check out our careers page here.
Tomorrow, August 26, marks Women’s Equality Day, but each day we are proud of the women who work to advance science and truly impact patient lives. We recently had the chance to hear from Ria Palarca and Nhu Truong on the importance of equal opportunity and a supportive workplace. Check out their perspectives below. […]
The Alzheimer’s disease space continues to buzz with news – advancements in the science and understanding of the disease, availability of new treatment options, and a newfound sense of hope for the Alzheimer’s community. In a recent interview with PharmaVoice, Prothena CEO Gene Kinney shares, “Science is an iterative process, and for a disease as […]
In this inspiring video, we hear how Mike’s amyloidosis has affected not only him, but his wife Donna and their marriage, too. In fact, they actually agree the diagnosis has brought them closer. Like many diseases, it is important to remember that amyloidosis changes the lives of more than just the patient. Donna, Mike’s primary […]
Throughout the last year, we’ve seen some of the most significant breakthroughs to date in Alzheimer’s disease research, most notably—solidifying that anti-Aβ is a viable and clinically-sound treatment pathway. This is only the beginning, and we at Prothena are both proud and excited to be a part of developing the next generation of therapies for […]
Prothena is working to develop new treatments for people facing some of the world’s most devastating diseases, including neurodegenerative diseases like Alzheimer’s and Parkinson’s. It’s a challenging mission that attracts people who are passionate and committed including Francisco Lio, our Senior Director, Global Program Manager, who manages interdisciplinary teams responsible for two promising Alzheimer’s […]
Like what you see? If you want to learn more about opportunities to join the #ProthenaProud team, check out our careers page here.
Q: Why is Prothena partnering with Walgreens? A: Our collaboration with Walgreens should accelerate patient identification and increase access and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial, which is evaluating the safety and tolerability of PRX012. PRX012 is a potential best-in-class anti-Aβ antibody under development for the treatment of Alzheimer’s disease […]
Prothena recently joined the Rare Disease Company Coalition, a coalition of companies dedicated to discovering, developing, and delivering rare disease treatments for the patients we collectively serve. “We are happy to welcome Prothena to the Coalition; they join us in our work to advocate for policies that enable positive changes to be realized for the […]
Q: What is ASPIRE? A: The Amyloidosis Stakeholder Partnerships for Impact Reach and Equity (ASPIRE) is a collaborative of biotech and pharmaceutical companies committed to improving diagnosis, systems of care, and health equity for patients suffering from amyloidosis, a rare disease caused by protein build-up. Q: What is ASPIRE’s goal? A: ASPIRE aims to accelerate […]
Light chain (AL) amyloidosis is a rare and progressive disease that interferes with normal organ function and lead to failure of vital organs, like the heart. Currently, there are no approved therapies that significantly improve survival. The impact of amyloidosis goes beyond health. Patients with AL amyloidosis experience frequent overall loss of productivity, missed work […]
In 1983, President Ronald Reagan, who himself succumbed to this cruel disease roughly two decades later, declared November to be National Alzheimer’s Disease Awareness Month. For nearly forty years, we’ve kept the 6.5 million Americans and 55 million people worldwide who suffer from this disease and their families in our thoughts during this month. But […]